

# UC Davis

## UC Davis Previously Published Works

### Title

Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research

### Permalink

<https://escholarship.org/uc/item/6t5444f6>

### Journal

Drug Metabolism and Disposition, 51(6)

### ISSN

0090-9556

### Authors

Cronin, Joseph M

Yu, Ai-Ming

### Publication Date

2023-06-01

### DOI

10.1124/dmd.122.001008

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <https://creativecommons.org/licenses/by-nc/4.0/>

Peer reviewed

## 50th Anniversary Celebration Collection

### Special Section on Perspective on Drug Metabolism and Disposition, Part I—Minireview

# Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research

 Joseph M. Cronin and  Ai-Ming Yu

*Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA (J.M.C., A.-M.Y.)*

Received June 23, 2022; accepted March 9, 2023

#### ABSTRACT

The development of safe and effective medications requires a profound understanding of their pharmacokinetic (PK) and pharmacodynamic properties. PK studies have been built through investigation of enzymes and transporters that drive drug absorption, distribution, metabolism, and excretion (ADME). Like many other disciplines, the study of ADME gene products and their functions has been revolutionized through the invention and widespread adoption of recombinant DNA technologies. Recombinant DNA technologies use expression vectors such as plasmids to achieve heterologous expression of a desired transgene in a specified host organism. This has enabled the purification of recombinant ADME gene products for functional and structural characterization, allowing investigators to elucidate their roles in drug metabolism and disposition. This strategy has also been used to offer recombinant or bioengineered RNA (BioRNA) agents to investigate the posttranscriptional regulation of ADME genes. Conventional research with small noncoding RNAs such as microRNAs (miRNAs) and small interfering RNAs has been dependent on synthetic RNA analogs that

are known to carry a range of chemical modifications expected to improve stability and PK properties. Indeed, a novel transfer RNA fused pre-miRNA carrier-based bioengineering platform technology has been established to offer consistent and high-yield production of unparalleled BioRNA molecules from *Escherichia coli* fermentation. These BioRNAs are produced and processed inside living cells to better recapitulate the properties of natural RNAs, representing superior research tools to investigate regulatory mechanisms behind ADME.

#### SIGNIFICANCE STATEMENT

This review article summarizes recombinant DNA technologies that have been an incredible boon in the study of drug metabolism and PK, providing investigators with powerful tools to express nearly any ADME gene products for functional and structural studies. It further overviews novel recombinant RNA technologies and discusses the utilities of bioengineered RNA agents for the investigation of ADME gene regulation and general biomedical research.

#### Introduction

The understanding of drug metabolism and pharmacokinetic (DMPK) processes represents a critical and necessary step in the development of new drugs. Elucidating these processes and understanding how they differ between species is key in translating basic scientific research into an efficacious and safe clinical treatment. The importance of DMPK in drug

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [R35-GM140835] and National Cancer Institute [R01-CA253230 and R01-CA225958]. J.M.C. was supported by a National Institutes of General Medical Sciences-funded Pharmacology Training Program grant [T32-GM144303].

No author has an actual or perceived conflict of interest with the contents of this article.

dx.doi.org/10.1124/dmd.122.001008.

development and safety was first made widely evident by the tragedy of thalidomide, a morning sickness drug developed with rat models that caused severe birth defects in humans (Speirs, 1962; Boylen et al., 1963). While the cytochrome P450 (CYP or P450) enzymes were identified and characterized spectroscopically in 1962, widespread appreciations of P450s in xenobiotic metabolism and interspecies differences in drug disposition had not yet been established (Omura and Sato, 1962). Further research with thalidomide determined that its teratogenic effect could be attributed to toxic metabolites discovered in the urine of treated animals (Gordon et al., 1981). Notably, this toxic bioactivation of thalidomide was absent in rat liver microsomes and only observed in rabbits, primates, and humans (Gordon et al., 1981). This tragedy and subsequent discovery illustrated the importance of interspecies differences in drug metabolism and resulting toxicity, driving forward DMPK research and influencing key regulatory law still in effect today.

**ABBREVIATIONS:** ADME, absorption, distribution, metabolism, and excretion; BioRNA, bioengineered RNA; cDNA, complementary DNA; CRISPR, clustered regularly interspaced short palindromic repeats; CYP or P450, cytochrome P450 monooxygenase; DDI, drug-drug interaction; DMPK, drug metabolism and pharmacokinetics; DDI, drug-drug interactions; FDA, Food and Drug Administration; mRNA, messenger RNA; miRNA, microRNA; ncRNA, noncoding RNA; NRF2, nuclear factor erythroid 2-related factor 2; ori, origin of replication; PK, pharmacokinetic; rDNA, recombinant DNA; siRNA, small interfering RNA; SRP, signal recognition particle; tRNA, transfer RNA; VDR, vitamin D receptor.




Fig. 1. Milestones of rDNA technologies and relevant applications to P450 and ADME research.

Soon afterward, key advancements in molecular biology and the subsequent birth of recombinant DNA (rDNA) technologies (Fig. 1) would equip DMPK researchers with the tools to investigate unprecedented research questions in drug metabolism and disposition (Guengerich, 2020). This was not limited to CYP enzymes but also included other genes and proteins involved in absorption, distribution, metabolism, and excretion (ADME) processes. Nucleotide sequencing technologies enabled the generation of complementary DNA (cDNA) libraries for CYP enzymes (Negishi et al., 1981; Gonzalez and Gelboin, 1992) (Fig. 1) and other ADME gene products for use in molecular cloning (Maniatis et al., 1983; Fothergill-Gilmore, 1993; Guengerich, 2020; Patil et al., 2022). Generated cDNA sequences were used to produce recombinant P450 enzymes through heterologous expression in model systems such as yeast (*Saccharomyces cerevisiae*) and *Escherichia coli* (*E. coli*) (White et al., 1984; Oeda et al., 1985; Unger et al., 1986; Gonzalez et al., 1988a,b; Umeno et al., 1988; Podust et al., 2001; Yu et al., 2002; Williams et al., 2003; Schoch et al., 2004). With previous research limited to the use of liver microsomes or P450s purified from the tissues (Lu and Coon, 1968; Estabrook, 2003; Coon, 2005), the development of rDNA strategies propelled the field forward by enabling the characterization of individual P450 enzymes in vitro (Fig. 1) (Oeda et al., 1985; Gonzalez et al., 1988a,b; Umeno et al., 1988; Barnes et al., 1991; Larson et al., 1991b; Li and Chiang, 1991; Scott et al., 2001; Guengerich, 2020). This approach proved to be a significant boon to the fields of DMPK, empowering researchers to interrogate key differences between human P450 reactions and those relevant to preclinical animal models (Guengerich, 2020). rDNA technologies have proven invaluable in the screening and hazard identification of countless drugs, enabling characterization of ADME gene products and arming medicinal chemists and pharmacologists with the knowledge of common moieties likely to undergo biotransformation.

While innovation in molecular biology has given researchers the tools to answer many questions regarding ADME genes and drug metabolism, it has also illuminated a complex system of drug disposition that varies widely across species, sex, and tissue type (Guengerich, 2020). Not only does the expression of individual CYP enzymes vary by organism and tissue, but their catalytic activity can show significant interspecies differences (Martignoni et al., 2006). Even within the same species, some CYP enzymes are highly polymorphic, exhibiting interindividual

variations as well as broader racial differences such as those in observed in poor CYP2D6 and CYP2C19 metabolizers (Nakamura et al., 1985; Gonzalez et al., 1988b). Further complicating matters, CYP enzyme expression can be induced through exposure to a wide variety of drugs and environmental chemicals (Graham and Lake, 2008). Although a variety of induction mechanisms have been elucidated, this largely occurs through xenobiotic interaction with nuclear receptors to drive an increase in CYP gene transcription (Dickins, 2004). Natural products have also been identified to inhibit critical drug-metabolizing CYP enzymes rather than induce them, with the most widely known example being grapefruit juice's inhibition of CYP3A4 (Guo and Yamazoe, 2004). Similar to expression level and catalytic activity, induction of CYP genes in response to environmental chemicals or drugs can vary widely between species as well as between individuals (Tang et al., 2005; Graham and Lake, 2008). Understanding these differences in ADME gene expression, protein activity, and gene regulation in response to chemicals is critical to designing safe drugs that account for species and individual differences in drug metabolism and toxicity.

Although significant advancements have been made, continuing to broaden our understanding of ADME gene regulation and function in DMPK is necessary to inform the development of safe and efficacious medications. When analyzed by exome sequencing, ADME genes were found to have significantly more variability and possible variants compared with non-ADME genes (Hovelson et al., 2017). ADME gene variations between individuals, populations, and species can have drastic effects on DMPK, therefore affecting therapeutic safety and efficacy. These variations between species can have a dramatic impact on the success of drug development, decreasing the face validity of preclinical animal models and negatively affecting whether scientific research can be translated into an effective clinical therapy. Approximately 54% of novel therapeutics failed in clinical development from 1998 to 2015, with the large majority of failures attributed to inadequate efficacy or safety (Hwang et al., 2016). In addition to this, therapies that were successfully approved took an average time of 17 years for research discoveries to reach the clinic (Morris et al., 2011). Recent updates to US Food and Drug Administration (FDA) guidelines have also removed the requirement that all drugs be tested in animals, instead welcoming more representative models of human disease such as organoid or organ-on-a-chip approaches (Wadman, 2023). Keeping these shortcomings in

mind, it is clear that novel technologies and approaches are needed to further elucidate ADME gene regulation and function in DMPK. Advancement of these fields is critical to educate researchers and improve the success rate of developing drugs, as well as shorten the lag time observed bringing a drug from “bench to bedside.” This mini-review examines rDNA technologies in the context of DMPK research, highlighting historical successes expressing recombinant proteins for structural and functional studies as well as discussing new recombinant RNA approaches that have offered unique RNA molecules to investigate ADME gene regulation and novel research questions.

### rDNA Technology

rDNA technology is characterized by altering genetic material outside an organism with the goal of transforming desired characteristics into a living organism or its products. Recombinant technologies would not be imaginable without those that laid the scientific foundation of how we understand heredity, genetics, and molecular biology. In this way, all modern successes of rDNA technologies stand on the shoulders of giants like Gregor Mendel that first began to elucidate these key genetic processes (Mendel, 1865). These researchers broadened the scientific understanding of genetics and DNA, enabling the development of critical technologies that set the stage for genomic sequencing, molecular cloning, and modern rDNA technologies.

**rDNA Technology: A Brief History.** In 1952, Joshua Lederberg proposed the term “plasmid” for an extrachromosomal genetic material that had been recently observed (Fig. 1) (Lederberg, 1952). At the time, no one could predict that the plasmid would one day become the workhorse at the center of countless recombinant technologies across a diverse range of industries. We know now that plasmids are circular, double-stranded DNA molecules naturally present in the cytoplasm of bacteria and other prokaryotes that are capable of replicating independently from the host cell (Fothergill-Gilmore, 1993; del Solar et al., 1998). Plasmids encode the information needed for their own replication and can confer specific characteristics to the host organism such as antibiotic resistance (Fothergill-Gilmore, 1993). However, research at the time of their discovery was hampered by a lack of viable strategies to introduce these circular double-stranded DNA molecules into cells (Patil et al., 2022). This research problem would lead to a monumental breakthrough for rDNA technologies by driving collaboration between experts in plasmid technology and targeted DNA manipulation (Patil et al., 2022). This collaboration and the intersection of these critical techniques resulted in the construction of the first biologically functional recombinant plasmid in vitro (Cohen et al., 1973) (Fig. 1). Restriction endonucleases EcoRI and EcoRII were used to cut the double-stranded plasmid, leaving single-stranded 3' and 5' sticky ends that could be joined together by DNA ligase to generate a circular double-stranded DNA molecule and functional plasmid (Cohen et al., 1973). This key experiment combined separate *E. coli* plasmid species pSC101 and pSC102, which contain genes encoding for resistance to tetracycline and kanamycin, respectively. The resulting biologically functional plasmid conferred resistance to both antibiotics, which was used to identify positive transformants via antibiotic treatment (Cohen et al., 1973). This represents the first use of what is commonly known now as a selection marker gene: a critical characteristic of plasmids and other cloning vectors that allows for selection of positively transformed cells. This approach utilizing selective advantage to identify positive transformants has proven invaluable to rDNA technologies and is still widely used today.

The following year, in 1974, this innovative strategy was successfully used to achieve the replication and transcription of eukaryotic *Xenopus*


*laevis* DNA in *E. coli* (Morrow et al., 1974). Detection of *X. laevis* rDNA in *E. coli* transformants from this experiment demonstrated that *E. coli* could be used to clone genes with eukaryotic species of origin (Morrow et al., 1974). The next logical step was to test whether this approach could be employed to not only transcribe a eukaryotic gene but also to express and produce human proteins. Shortly after, the human hormone somatostatin was successfully cloned in *E. coli* using a pBR322 plasmid vector, demonstrating that rDNA technologies could be used to produce functional human proteins (Itakura et al., 1977) (Fig. 1). Only a few years later, Genentech's recombinant human insulin named Humulin gained US FDA approval and entered the US market (Goeddel et al., 1979). This landmark advancement in rDNA technology would serve as the inspiration for the development of countless biotechnologies, showcasing vector-driven transformation in microorganisms like *E. coli* as a robust strategy to achieve the expression of a human gene product. With 621 biologic drugs currently FDA approved in the United States, it is clear these initial advances in rDNA technologies have inspired decades of innovative scientific research (FDA, 2021).

**Expression Vectors: Characteristics and Examples.** Since a bacterial plasmid was first used to express a eukaryotic gene in *E. coli*, our understanding of plasmids and other cloning vectors has greatly advanced. The bacterial plasmid was the first vector identified and optimized for the purpose of expressing recombinant gene products. However, there are also components present in the genomes of bacteriophages, yeasts, and viruses that can be used to accomplish effective transfer, cloning, and expression of a transgene in a heterologous system (Vieira and Messing, 1982; Patil et al., 2022). Specialized vectors that are optimized for transgene expression in a desired host organism are referred to as expression vectors and often contain additional non-coding sequences such as promoters, enhancers, and exons from the parent sequence that improve the transcription or expression of the gene product (Patil et al., 2022). Although vectors vary in their source, size, structure, capacity, and replication efficiency, all of them must retain several key attributes. To facilitate the discussion of key vector principles and their impact on successful transformation and expression of a gene insert, we refer to the widely used and iterated-upon plasmid pBR322 as an example (Fig. 2). This was one of the first vectors constructed with the intent of generating and selecting for recombinant clones, with pBR322 and its derivatives such as the pUC plasmids being commercially available and still widely used in rDNA technologies today (Balbás et al., 1986).


Notable sequences used to construct the pBR322 plasmid include the ampicillin resistance gene (*amp<sup>R</sup>*), a promoter from the ColE1-related plasmid named pRSF214, and the tetracycline resistance gene (*tet<sup>R</sup>*) from the pSC101 plasmid discussed earlier (Cohen et al., 1973; Bolivar et al., 1977a,b) (Fig. 2). As established, cloning and expression vectors must contain a selection marker gene that confers a selective advantage to vector-bearing host cells (Cohen et al., 1973; Patil et al., 2022). Selection markers commonly encode antibacterial resistance or metabolic advantages, providing a survival advantage to positive transformants so they can be selected for through antibiotic treatment or nutrient deprivation (Bolivar et al., 1977b; Fothergill-Gilmore, 1993; Patil et al., 2022) (Fig. 2). Strategies to select for recombinant clones are not only limited to those providing a survival advantage to positive transformants, with other successful selection approaches utilizing targeted DNA insertion to functionally disrupt a gene (Bolivar et al., 1977b). This can confer traits to positive transformants that allow for their negative selection, such as tetracycline sensitivity in *tet<sup>R</sup>* disruption and the formation of colorless colonies when the gene encoding the alpha protein of beta-galactosidase is disrupted (Bolivar et al., 1977b; Vieira and Messing, 1982).

In addition to containing a selection marker gene, a suitable expression vector must also be able to replicate in the host organism of choice.

A



B



**Fig. 2.** Recombinant protein expression vectors: Characteristics and examples in P450 research. (A) First-generation vector pBR322 contains an ampicillin resistance gene (AmpR) and a tetracycline resistance gene (TcR), both shown in green. These genes serve as selection markers to identify positive transformants upon antibiotic treatment. The pBR322 plasmid contains a ColE1 ori site, which is illustrated in yellow. This ori site is recognized by *E. coli* host machinery to enable replication of the plasmid in this model organism. The repressor of primer (rop) gene illustrated in red encodes the rom protein, which limits the copy number of this vector. (B) An optimized expression vector derived from pCWori+ is used to construct target plasmid toward heterologous P450 expression in *E. coli* (von Wachenfeldt et al., 1997). This vector contains two tac promoter sequences that are under transcriptional control of the lac repressor protein, which is illustrated in red (Barnes et al., 1991). The lac repressor is encoded by the lacI<sup>q</sup> gene shown in green, which suppresses transcription until an inducing agent such as isopropyl β-D-thiogalactopyranoside is added. The vector and recombinant P450 gene insert are digested with endonucleases NdeI and EcoRI, enabling insertion and ligation of the transgene downstream of the two inducible tac promoters. This pCWori+ derived expression vector also possesses two ori sites shown in yellow, which include the previously discussed ColE1 ori as well as an F1 ori that provides a recognition site for M13 bacteriophages.

In plasmids, phagemids, and bacteriophage-based vectors, this is ensured through the inclusion of an origin of replication (ori) site (Patil et al., 2022). The ori site is recognized by host replication machinery, serving as a point of assembly for the components involved in DNA replication (del Solar et al., 1998; Patil et al., 2022). Some ori sites are specific to a certain host bacteria, while others are able to be recognized by the replication machinery of multiple species (Patil et al., 2022). The ori site in the pBR322 plasmid is derived from the ColE1 plasmid native to *E. coli*, making it a suitable choice for cloning and expression in this host organism (Bolivar et al., 1977b) (Fig. 2). The inclusion of more than one ori site in a cloning vector can allow replication across multiple different host species, expanding the flexibility of vectors for use in other model systems. The ori sites within expression vectors are often optimized for more efficient recruitment of replication components, with these sequences having a dramatic effect on the copy number of the vector (Friehs K, 2004; Patil et al., 2022). Another determinant of pBR322's copy number is encoded by the repressor of primer (*rop*) gene shown in red (Cesareni et al., 1982; Banner et al., 1987) (Fig. 2). The protein encoded by this gene regulates plasmid copy number by promoting interaction of inhibitory RNA components that prevent primer maturation to modulate plasmid replication (Banner et al., 1987; Helmer-Citterich et al., 1988; del Solar and Espinosa, 2000). This limits the copy number of pBR322, a disadvantage in cloning that would be addressed by future derivatives of this vector.

Expression vectors must also contain multiple cloning sites that serve as unique locations for restriction endonucleases to recognize, enabling the specific digestion of the plasmid at these sites to generate a linearized double-stranded DNA molecule. The transgene of interest is digested using the same restriction enzymes to enable gene insertion into the plasmid. The compatible ends generated by restriction digest are joined together by DNA ligase, creating a recombinant vector that can undergo replication using host machinery (Fothergill-Gilmore, 1993; Patil et al., 2022) (Fig. 2). The pBR322 plasmid has been optimized to include a variety of multiple cloning sites for gene insertion, with many of them falling within critical segments of the vector, including both antibiotic resistance genes, the *amp<sup>R</sup>* promoter, and the origin of replication (Bolivar et al., 1977b) (Fig. 2). The functional disruption of the *tet<sup>R</sup>* gene via DNA insert that was discussed earlier utilizes the unique multiple cloning sites present within this gene. This allows for identification of host cells bearing the plasmid that contains the transgene DNA insert, with positive pBR322 transformants that successfully inserted and ligated the DNA fragment via HindIII, SalI, or BamHI endonucleases no longer having a functional *tet<sup>R</sup>* gene (Bolivar et al., 1977b; Patil et al., 2022). This creative utilization of multiple cloning sites to generate specialized selection markers highlights the vast utility of restriction endonucleases, not only proving invaluable to the targeted insertion of a transgene but also in the customization of expression vectors and their features. While there are many context-specific applications of these enzymes and the cloning sites they recognize, this general strategy of enzyme-mediated transgene insertion, ligation, and replication has been widely applied in the cloning and expression of countless gene products as therapeutics and for functional study, including those integral to ADME processes such as P450 enzymes (Oeda et al., 1985; Unger et al., 1986; Gonzalez et al., 1988b) (Fig. 2).

In addition to the discussed components, an effective expression vector must also promote the efficient expression of the inserted transgene in the host system. Inclusion of a strong promoter that is compatible with the host species is critical to achieve adequate expression of a recombinant gene product (Fothergill-Gilmore, 1993). The promoter sequence must also be compatible with the modality of the gene product, with different promoters being used depending on whether the recombinant gene product is a protein, messenger RNA (mRNA), or small interfering RNA

(siRNA; Patil et al., 2022). Some specialized expression vectors can also be designed with dual-promoter systems that aim to further increase the strength of transgene expression (Öztürk et al., 2017). These dual-promoter systems can consist of two twin promoters activated under the same conditions, as well as two nonidentical promoters activated during separate steps to aid production processes in biotechnology (Öztürk et al., 2017). Similarly, the inclusion of a strong termination sequence following the promoter and transgene can enhance expression and represents an important component of an efficient vector (West and Proudfoot, 2009; Gasanov et al., 2015; Patil et al., 2022). As recombinant technologies have continued to advance, expression vectors have become more readily adaptable tools that can be customized to efficiently express a wide variety of transgene products across many host systems. Recently developed expression vectors may also aid the purification of recombinant proteins through the installation of a polyhistidine affinity tag. Once purified, the affinity tag can be cleaved by tobacco etch virus protease to return the recombinant protein to its native conformation (Rocco et al., 2008). This strategy has been used to generate several novel expression vectors from the pET series capable of expressing and more easily purifying recombinant proteins (Rocco et al., 2008).

Like the choice of expression vector, choosing an appropriate host organism for transgene expression is a critically important step when utilizing rDNA technologies. Different model organisms possess distinct characteristics that can make them best suited to a particular application or gene product (Fothergill-Gilmore, 1993). Model organisms for recombinant expression can vary in their yield capacity, post-synthetic modification capability (glycosylation, acetylation), ability to secrete active proteins, and ability to express specific gene products or modalities. Common model species for transgene expression include bacteria (*E. coli*, *Lactococcus lactis*, *Pseudomonas*), yeast (*Saccharomyces cerevisiae*), mammalian cells (CHO, human embryonic kidney, COS), and insect cells (Sf9) (Koga et al., 1985; Oeda et al., 1985; Wurm, 2004; Chen, 2012). Research efforts continue to improve upon these expression systems and remedy their shortcomings. One of the most relevant examples of this is in *E. coli*, where advancements have enabled glycosylation of protein products and the use of antibiotic-free selection plasmids (Chen, 2012).

**Applications of rDNA Technology in DMPK Research.** Since the inception of rDNA technology, innovative researchers have been developing creative ways to adapt the rDNA platform to address their research questions with cDNA-expressed P450s (Fig. 1). One critical example of this was the development of site-specific mutagenesis methods utilizing M13 bacteriophage cloning vectors (Hutchison et al., 1978; Zoller and Smith, 1982). This method is used to elicit specific and targeted changes to a gene of interest for transformation into *E. coli* and other model organisms (Hutchison et al., 1978; Zoller and Smith, 1982). With the ability to introduce targeted single-nucleotide changes to any DNA fragment, researchers were able generate novel mutants for functional study. Often this approach is used to investigate the role of individual amino acid residues in contributing to the function or interactions of a specific protein. In DMPK research, this method has been used to generate novel P450 mutants to elucidate the role that specific residues play in protein behavior and enzyme function (Wilderman et al., 2012). Site-directed mutagenesis has also been widely applied in the characterization of other ADME related proteins such as ABC transporters and multidrug efflux pumps (Yao et al., 2013; Cox et al., 2018). Distinct from site-directed mutagenesis, random mutagenesis has also been used in DMPK research to generate novel CYP enzymes capable of withstanding harsh environmental conditions and performing biotransformations previously unseen in nature (Giver et al., 1998; Joo et al., 1999; Brandenburg et al., 2017; Arnold, 2018). Through many

cycles of random mutagenesis and screening, beneficial mutations are accumulated that alter metabolic function and often promote an intrinsic promiscuity or side-reactivity of the natural enzyme (Arnold, 2018). This strategy developed by Frances Arnold is termed directed evolution, and it was awarded the 2018 Nobel Prize in chemistry. This innovative approach has been used to develop novel CYP enzymes capable of catalyzing many new and nonnatural reactions such as those valuable to medicinal chemistry or biotechnology processes (Brandenberg et al., 2017; Arnold, 2018).

Another valuable application of rDNA technologies in DMPK research has been improving the field's access to robust research tools. A prominent example of this is the production of recombinant antibodies and nanobodies utilizing phage or yeast display libraries (Marks et al., 1991; McMahon et al., 2018). Specific and sensitive antibodies are critical reagents for any biomedical research, serving as important probes to detect and quantify target antigens. Recombinant antibodies may also serve as inhibitors to block specific protein-protein interactions, proving useful in elucidating the role of specific protein epitopes and interactions in determining protein function (Basu et al., 2019).

Previous methods of antibody production relied on hybridoma technology, requiring mature B cells be harvested from an animal immunized with the antigen (Basu et al., 2019). Because this relies on host immunization, the antibody generated is in response to host presentation of the antigen via the major histocompatibility complex. The antigen must undergo proteolysis to a smaller peptide for host presentation to occur, and because of this the antibodies generated by hybridoma methodology do not always successfully recognize the native conformation of the antigen they target (Roche and Furuta, 2015; Basu et al., 2019). However, when generating recombinant antibodies by phage display, the antigen of interest is present in its native conformation and is less likely to undergo alteration compared with hybridoma approaches (Basu et al., 2019). This represents a distinct advantage of recombinant antibody production when compared with previous hybridoma methods, especially when considering the importance of conformation in ADME-related protein function. Additionally, recombinant antibody production is significantly cheaper, does not require the use of animals, and allows for the inclusion of additional features such as an amino acid tag to aid the purification process (Basu et al., 2019).

This success utilizing rDNA technology to develop superior research tools has not only occurred with antibodies but has also extended to other modalities such as microRNAs (miRNAs), siRNAs, and aptamers (Ho and Yu, 2016). miRNAs are understood as epigenetic regulators with a vast array of targets and functions, with one miRNA able to regulate several mRNA transcripts at the posttranscriptional level (Ali Syeda et al., 2020; Yu et al., 2020). Understanding miRNA's role in ADME gene regulation and function is critical to addressing a comprehensive picture of DMPK. The field of miRNA research has been somewhat limited by the widespread usage of chemically synthesized miRNA mimics as research tools. These commercially available miRNA mimics carry extensive chemical modifications that are needed to improve their stability and PK properties (Khorova and Watts, 2017; Yu et al., 2019). The way in which these synthetic mimics are modified is not always disclosed, and modifications between manufacturers can vary in identity, location, and number (Yu et al., 2019). Although the nucleotide sequence is unaffected, these inconsistent modification practices generate miRNAs that are constitutively different from natural miRNAs and may lead to conflicting results between investigators (Yu et al., 2019; Diener et al., 2022; Traber and Yu, 2023).

To address these shortcomings, the Yu laboratory has developed an innovative bioengineering platform to express and purify recombinant miRNA molecules in *E. coli* (Li et al., 2021; Tu et al., 2021). Echoing

the success of biologic proteins, these miRNAs are synthesized and folded inside living cells and better recapitulate the structures, modifications, and properties of endogenous miRNAs and thus represent superior tools for DMPK research and as potential therapeutics (Yu et al., 2019). Later in this review, we discuss the optimization of this recombinant strategy as well as its utilization in elucidating the impact of endogenous miRNA on ADME gene regulation and DMPK.

In addition to developing improved tools and reagents for research, advancements in rDNA technologies have also enabled novel approaches to generate improved cellular and animal models for the study of drug metabolism and human disease (Gonzalez and Yu, 2006; Dorr et al., 2017; Sundhari et al., 2019; Lu et al., 2021). One prominent advancement is the 2020 Nobel Prize winner in chemistry, an adaptable gene editing platform that utilizes clustered regularly interspaced short palindromic repeats (CRISPR) associated with a Cas9 endonuclease (Westermann et al., 2021). This promising technology commonly known as CRISPR-Cas9 has gained widespread popularity over the past decade, with many ex vivo gene therapies that use the platform currently undergoing clinical trials across a variety of disease states (Li et al., 2020). In the context of DMPK research, this targeted gene editing technology has been used to generate valuable in vivo and in vitro knockouts to characterize individual ADME gene and allele function (Religia et al., 2021). Examples of ADME gene products knocked out or modified for functional study using CRISPR-Cas9 include CYP enzymes, ABC transporters, nuclear receptors, and solute carrier proteins (Karlgren et al., 2018; Wei et al., 2018; Liang et al., 2019; Karakus et al., 2020; Salanga et al., 2020; Lu et al., 2021). This approach can accomplish specific knockout of individual or multiple alleles of a target gene, allowing researchers to interrogate their role in xenobiotic metabolism, drug-drug interactions (DDIs), and PK (Dorr et al., 2017; Lu et al., 2021). While the CRISPR/Cas9 platform holds great promise to enable research and treat genetic disorders, future iterations of the technology must continue to improve upon its accuracy and precision as well as address concerns surrounding its unintended epigenetic impact (Doudna, 2020).

### Recombinant ADME Proteins for Functional and Structural Studies

Before rDNA technologies gained widespread usage in the development of therapeutics and research tools, these recombinant advancements were used in the functional and structural study of ADME gene products such as CYP enzymes (Fig. 1). Indeed, early research of P450 enzymes before rDNA technology was limited to approaches such as preparing microsomes and purifying individual CYPs from animal tissues (Lu and Coon, 1968). This strategy proved effective in reconstituting soluble cytochrome P450 enzymes with intact catalytic activity, allowing researchers to study P450-mediated biotransformation of endogenous compounds and xenobiotics alike (Lu and Coon, 1968; Lu et al., 1969; Guengerich, 1977). Additionally, these early works from Lu and Coon identified the necessary components that constitute catalytic activity in liver microsomes: P450 hemoprotein, cytochrome c reductase, and a heat-stable factor (Lu and Coon, 1968). These research efforts broadened the field's understanding of in vivo drug metabolism by identifying numerous unique forms of soluble P450 enzymes, elucidating key components critical to catalytic activity, and illuminating characteristic differences between species (Lu and Coon, 1968; Haugen et al., 1975; Ryan et al., 1975; Guengerich, 1977).

**Microbial P450<sub>CAM</sub>: A Window Into P450 Structure and Function.** Despite some success with liver microsomes, the DMPK field was in need of a more suitable model system for the structural and

TABLE 1  
Expression of some recombinant P450 monooxygenases for structural or functional studies

P450 Enzyme	Species of Origin	Investigative Area	Host Organism	References
P450 <sub>CAM</sub>	<i>P. putida</i>	Crystal structure of three named orientations of the enzyme	<i>P. putida</i>	(Poulos et al., 1982)
P450 <sub>C21</sub>	Bovine	Genetics of adrenal P450 steroid 21-hydroxylation	<i>E. coli</i>	(White et al., 1984)
Microsomal P450	Rabbit	Role of NH2 terminus (SRP) in membrane solubility	SP-6 transcription vector (in vitro)	(Sakaguchi et al., 1984; Sakaguchi et al., 1987)
P450 <sub>MC</sub>	Rat	Role of NH2 terminus (SRP) in catalytic activity	<i>Saccharomyces Cerevisiae</i>	(Oeda et al., 1985)
P450PCN1	Human	Drug metabolism activity	COS cells	(Gonzalez et al., 1988a)
CYP2D6	Human	Enzyme function and genetic polymorphism	COS cells	(Gonzalez et al., 1988b)
CYP2E1	Human	Function in drug metabolism	COS cells	(Umeno et al., 1988)
CYP2E1	Rabbit	Role of NH2 terminus (SRP) in catalytic activity (NDMA deethylation)	<i>E. coli</i>	(Larson et al., 1991b)
CYP51	Mycobacterium tuberculosis	Crystal structure, expression of soluble MT form, substrate requirements	<i>E. coli</i>	(Podust et al., 2001)
CYP2B4	Rabbit	Crystal structure, conformational flexibility at active site	<i>E. coli</i>	(Scott et al., 2003)
CYP2C5	Rabbit	Crystal structure, expression of NH2 truncated form	<i>E. coli</i>	(Williams et al., 2000)
CYP2C9	Human	Crystal structure, binding pocket in the presence of warfarin	<i>E. coli</i>	(Williams et al., 2003)
CYP2C8	Human	Crystal structure, ligand-induced conformational changes	<i>E. coli</i>	(Schoch et al., 2004)
CYP2D6	Human	Crystal structure, specificity of ligand binding	<i>E. coli</i>	(Rowland et al., 2006)
CYP2D6.1, 2, 10, and 17	Human	Functions of allelic isoforms and genetic polymorphism	<i>T. ni</i> (insect)	(Yu et al., 2002)
CYP3A4	Human	Crystal structure in multiple conformational states, residues involved in midazolam oxidation	<i>E. coli</i>	(Khan et al., 2002; Williams et al., 2004)
CYP3A4/5	Human	Differences in active site plasticity and substrate binding complexed with Ritonavir	<i>E. coli</i>	(Hsu et al., 2018)
CYP3A7	Human	Crystal structure, comparative analysis of ligand binding	<i>E. coli</i>	(Sevrioukova, 2021)
CYP17A1	Human	Crystal structure, complexed with major substrates and inhibitors	<i>E. coli</i>	(DeVore and Scott, 2012)
CYP19A1	Human	Crystal structure, functional roles of key residues	<i>E. coli</i>	(Lo et al., 2013)
CYP11B1	Human	Crystal structure, cortisol synthesis	<i>E. coli</i>	(Brixius-Anderko and Scott, 2019)
CYP11B2	Human	Crystal structure, aldosterone synthesis	<i>E. coli</i>	(Brixius-Anderko and Scott, 2021)
CYP8B1	Human	Crystal structure, bile acid synthesis	<i>E. coli</i>	(Liu et al., 2022)

NDMA, N-Nitrosodimethylamine; SRP, signal-recognition particle; *T. ni*, *Trichoplusia ni*.

functional characterization of individual P450 enzymes (Poulos et al., 1982). This role would be filled by the microbial cytochrome P450<sub>CAM</sub>, a camphor-metabolizing monooxygenase that was identified in *Pseudomonas putida* (Gunsalus and Wagner, 1978; Poulos et al., 1982, 1987) (Table 1). This enzyme was purified for study prior to the advent of rDNA technologies and instead was isolated from bacterial culture according to a procedure optimized by Gunsalus and Wagner (Gunsalus and Wagner, 1978). P450<sub>CAM</sub> was the first CYP enzyme that had been purified in both soluble and crystalline forms, making it an ideal biologic model to study P450 structure and function (Gunsalus and Wagner, 1978; Poulos et al., 1982, 1985). High-resolution crystal structures were generated of P450<sub>CAM</sub> both bound to camphor and in the absence of its substrate, providing valuable insight into the substrate binding site and the structure-function relationship of the enzyme (Poulos et al., 1986, 1987). This crystallography data also elucidated the secondary structures and overall conformation of the polypeptide, illustrating important structural features of the enzyme such as the oxygen/heme binding pocket as well as a metal cation interaction that may stabilize active site formation (Poulos et al., 1987).

These advancements in P450<sub>CAM</sub> visualization were also paired with amino acid sequencing techniques, further improving the detail of structural and functional characterization and enabling the comparison of P450<sub>CAM</sub> to eukaryotic P450 sequences (Poulos et al., 1987). Compared P450 sequences were found to be fairly homologous, with residues that

form the oxygen binding area being highly conserved between species (Poulos et al., 1987). Amino acid sequencing also revealed that eukaryotic P450s uniquely possess a hydrophobic NH2 terminus, a domain that was speculated at the time to contribute to the membrane solubility observed in mammalian P450s (Poulos et al., 1987). While bacterial cytochrome enzymes like P450<sub>CAM</sub> are easily solubilized in the cytoplasm, eukaryotic P450 enzymes reside in the membranes of the endoplasmic reticulum and to a lesser extent the mitochondria (Lee et al., 1981). The functional role that this hydrophobic NH2 terminus plays in mammalian P450 membrane association and its effect on catalytic activity would later be elucidated using rDNA technologies (Oeda et al., 1985; Sakaguchi et al., 1987). P450<sub>CAM</sub> has also served as an effective model system to assess the role of accessory proteins, with crystal structures of the enzyme complexed to its redox partner putidaredoxin providing insight into the structural changes induced by putidaredoxin and how they may facilitate electron transfer (Hiruma et al., 2013; Tripathi et al., 2013). Even today, P450<sub>CAM</sub> is used as a model system to further investigate the allosteric roles of accessory proteins and how they may impact conformational dynamics (Poulos and Follmer, 2022).

Although P450<sub>CAM</sub> was purified from a gram-negative bacterium, its extensive study aided our understanding of mammalian P450 enzymes by enabling the thorough characterization of well-conserved domains and functions (White et al., 1984; Black and Coon, 1987; Poulos et al., 1987; Gonzalez et al., 1988a,b; Umeno et al., 1988; Gonzalez and Gelboin,



1992). With isolation of pure P450 enzymes from human tissue being an arduous and time-consuming process, this P450<sub>CAM</sub> model system was invaluable in establishing initial structure-function relationships and elucidating the basic catalytic mechanism conserved across nearly all P450s (Guengerich, 2020; Poulos and Follmer, 2022). P450<sub>CAM</sub> was also one of the first P450 enzymes cloned for recombinant expression, utilizing a plasmid-derived vector under strict promoter control to produce catalytically active P450 monooxygenase in *P. putida* and *E. coli* host systems (Koga et al., 1985; Unger et al., 1986). This was not the only microbial P450 enzyme investigated utilizing rDNA technologies, as the crystal structure of the prokaryotic form of 14 $\alpha$ -demethylase (CYP51) present in *Mycobacterium tuberculosis* was also elucidated this way (Podust et al., 2001) (Table 1). While CYP51 exists in most species as a membrane-bound enzyme that is localized to microsomes, the *Mycobacterium tuberculosis* genome possesses a uniquely soluble form of the enzyme that was expressed in *E. coli* for easier determination of the crystal structure (Bellamine et al., 1999; Podust et al., 2001). This newfound structural information would inform rational drug design of improved antifungal agents that target CYP51.

**cDNA Directed Expression of Mammalian P450 Proteins.** Not long after the crystal structure and amino acid sequence of P450<sub>CAM</sub> were elucidated, rDNA strategies gained widespread usage in the study of mammalian CYP enzyme structure and function in drug metabolism (Fig. 1) (Sakaguchi et al., 1984; White et al., 1984; Oeda et al., 1985; Gonzalez et al., 1988a,b; Umeno et al., 1988; Larson et al., 1991b; Khan et al., 2002; Wester et al., 2002; Yu et al., 2002; Scott et al., 2003; Williams et al., 2003, 2004; Schoch et al., 2004) (Table 1). Although some P450 amino acid sequences had been elucidated through methods discussed earlier, the development of cloning, nucleotide sequencing, and DNA manipulation technologies would equip researchers with powerful tools to generate libraries of P450 cDNA sequences (Poulos et al., 1987; Gonzalez and Gelboin, 1992; Poulos and Follmer, 2022). Complementary DNA sequences for human P450 enzymes were generated using mature mRNA from liver and lung tissue lysates (Gonzalez and Gelboin, 1992). Purified mRNA was then used to generate cDNA strands via reverse transcriptase, which then underwent amplification by polymerase chain reaction to generate double-stranded DNA fragments (Patil et al., 2022). These gene segments were then ready to be digested with complementary endonucleases and ligated into a vector for transformation of the amplified cDNA into a suitable host organism (Unger et al., 1986; Gonzalez and Gelboin, 1992; Patil et al., 2022). Due to observed sequence homology between species, human P450 sequences could be identified from these libraries through the use of cDNA probes and antibodies against rodent forms of P450 (Gonzalez et al., 1988b; Gonzalez and Gelboin, 1992). Once cDNA sequences of interest were identified and cloned using this approach, researchers set out to optimize the expression of these recombinant gene products in model organisms so their catalytic activities, substrate specificities, and structure-function relationships could be characterized (White et al., 1984; Oeda et al., 1985; Gonzalez et al., 1988a,b; Gonzalez and Gelboin, 1992; Schoch et al., 2004; Guengerich, 2020).

One important example that used cDNA-directed expression to illuminate P450 structure was the investigation of rabbit microsomal P450 and its cotranslational insertion into rough microsomes from dog pancreas (Sakaguchi et al., 1984, 1987) (Table 1). This would serve as an effective model of mammalian P450 integration into membranes of the endoplasmic reticulum, allowing researchers to interrogate the role of key structural features responsible for initiating cotranslational insertion and for conferring membrane solubility. Initial research demonstrated that cotranslational insertion of P450 could not occur without the presence of a ribonucleoprotein complex referred to as the signal

recognition particle (SRP) (Sakaguchi et al., 1984). However, further investigation was required to identify the way in which microsomal P450 recognizes the SRP to influence P450 function and membrane topology. Hybrid cDNAs were generated to express chimeric forms of the P450 protein for study, with each mutant possessing unique modifications impacting the length and identity of the N-terminal amino acid chain (Sakaguchi et al., 1987). Of the several chimeric P450 proteins generated, only those possessing an NH2 terminus at least 29 AAs in length were able to cotranslationally insert into the membrane (Sakaguchi et al., 1987). This demonstrated that the insertion signal that enables SRP-mediated cotranslation to the membrane was contained within this 29 AA segment of the enzyme's NH2 terminus (Sakaguchi et al., 1987). This research broadened the understanding of the NH2 terminus present in eukaryotic P450 forms, demonstrating the impact that NH2 truncation has on their topogenic function and membrane solubility (Sakaguchi et al., 1987).

Interestingly, recombinant research efforts expressing rat P450<sub>MC</sub> in *Saccharomyces cerevisiae* also generated a truncated form of the enzyme that lacked an extended NH2 terminus (Oeda et al., 1985). Spectral and catalytic analysis revealed almost identical properties between the truncated and nontruncated forms of the enzyme, demonstrating that this NH2 terminus is not required for P450 catalytic activity (Oeda et al., 1985) (Table 1). This knowledge would be widely applied to solubilize mammalian P450 through deletion of the NH2 terminus, allowing researchers to more easily purify and crystallize mammalian P450 enzymes for structural and functional characterization (Larson et al., 1991b; Hsu et al., 1993; Richardson et al., 1995; von Wachenfeldt et al., 1997; Williams et al., 2000; Podust et al., 2001; Wester et al., 2002, 2003, 2004; Scott et al., 2003; Williams et al., 2003, 2004; Schoch et al., 2004; Rowland et al., 2006; Hsu et al., 2018). This cDNA-directed approach would soon be used to express truncated rabbit CYP2E1 in *E. coli* using a pKKHC vector, an optimized derivative of the pBR322 plasmid discussed earlier (Larson et al., 1991a,b) (Table 1). These research efforts further supported the notion that the NH2 terminus is not necessary to retain P450 monooxygenase function, with recombinant truncated CYP2E1 possessing identical spectral and catalytic properties compared with full-length CYP2E1 isolated from rabbit liver microsomes (Larson et al., 1991a,b).

Similar success was also achieved in the recombinant expression of rabbit CYP2C3 as a soluble dimer in *E. coli*. The CYP2C3 gene insert with a modified NH2 terminus was digested with endonucleases NdeI and EcoRI and transformed into an optimized pCWOri+ vector that had been linearized with the same enzymes (von Wachenfeldt et al., 1997) (Fig. 2). This general procedure is highlighted in Fig. 2, serving as an example of heterologous P450 expression in *E. coli*. Additionally, the key components of this vector that allow for strong transgene expression and inducible control are summarized in Fig. 2. This pCWOri+ derived expression vector would also later prove useful in the recombinant study of CYP2C5 (von Wachenfeldt et al., 1997; Wester et al., 2002, 2003).

Not long afterward, two mammalian P450 enzyme crystal structures (CYP2B4, CYP2C5) were identified through recombinant expression in *E. coli* (Wester et al., 2002, 2003; Scott et al., 2003) (Table 1). Both enzymes were expressed in soluble form through truncation of the NH2 terminus, allowing for their crystallization and structural characterization. Crystallization in the presence and in the absence of substrate allowed investigators to examine conformational differences that can determine substrate recognition and catalytic function (Wester et al., 2003). These experiments were also one of the first to add a histidine tag to the C terminus of the recombinant protein to aid the purification process (von Wachenfeldt et al., 1997). This strategy would also be employed in the study of human CYP2C8, which was uniquely expressed

in *E. coli* as stable homodimer complexed by two palmitic acid molecules (Schoch et al., 2004). These peripheral fatty acid binding sites can alter characteristics of the active site and have potential to modulate substrate binding as well as contribute to DDIs (Schoch et al., 2004) (Table 1). This observed dimerization of CYP2C8 in addition to its significantly larger active site cavity suggest a distinct metabolic function of this enzyme when compared with previously elucidated P450s. This makes sense when considering that the primary substrates of CYP2C8 are comparatively larger molecules such as taxol (Schoch et al., 2004). Further research crystallized CYP2C8 with a variety of different substrates to examine the role of protein flexibility and ligand-induced conformational changes in accomplishing substrate oxidation (Schoch et al., 2008).

The crystal structure of human CYP2C9 was also determined through heterologous expression of a NH2 truncated mutant, which revealed a similarly large active site capable of accommodating multiple warfarin molecules or an additional substrate of similar size (Williams et al., 2003) (Table 1). Given that CYP2C9 can be activated by some exogenous compounds including warfarin, it was hypothesized that the binding of some ligands may serve an allosteric function that promotes enzyme activity (Williams et al., 2003). Compared with CYP2C9, the crystal structure of recombinantly expressed human CYP3A4 revealed a slightly smaller active site as well as a characteristic cluster of phenylalanine residues above it, some of which are known to cooperate in enzyme selectivity and function (Khan et al., 2002; Williams et al., 2004). X-ray crystallography data were generated for CYP3A4 in the absence of ligand, in the presence of an inhibitor metyrapone, and with its substrate progesterone (Williams et al., 2004) (Table 1).

To determine how the properties and structures of CYP3A4 and CYP3A5 differ, both enzymes were recombinantly expressed in *E. coli* and complexed with a high-affinity substrate ritonavir (Hsu et al., 2018). Crystallography data for these enzymes revealed differences in the shape and plasticity of their active sites upon substrate binding (Hsu et al., 2018) (Table 1). This structural data may reflect notable differences in the substrate dynamics and catalytic accessibility of these enzymes, potentially leading to divergent metabolic pathways or varying enzymatic efficiencies for shared metabolic pathways (Hsu et al., 2018). Additionally, enzymes of the CYP3A family can be differentially expressed across ethnic populations, with allelic variations having a significant effect on enzyme abundance and metabolic capability (Hirota et al., 2004; Yamaori et al., 2005). Given that the CYP3A family is the largest single contributor to drug metabolism, illuminating the structural features and processes that govern their catalytic activity and specificity is critically important in designing safe therapies, predicting DDIs, and understanding individual differences in drug metabolism (Zanger et al., 2008).

One recent advancement in the structural understanding of this enzyme family is the solved crystal structure of neonatal CYP3A7, a critical enzyme in hormone homeostasis and pediatric drug metabolism (Li and Lampe, 2019; Sevrioukova, 2021). Structural characterization of CYP3A7 was previously lacking, as the enzyme proved difficult to crystallize in its wild-type form. Using site-directed mutagenesis, a recombinant CYP3A7 variant capable of crystallization was generated to allow for structural characterization and comparison with other CYP3A enzymes (Sevrioukova, 2021) (Table 1). In many ways rDNA technologies have provided unprecedented insight into the catalytic structure, conformational dynamics, and substrate specificities of the most integral drug-metabolizing enzymes. Even today we continue to build upon our understanding of P450 monooxygenases, with recent investigations providing additional context regarding the nature of active site plasticity and redox partner selectivity (Poulos and Follmer, 2022).

Another cytochrome P450 enzyme that performs a significant share of xenobiotic biotransformations is human CYP2D6, as it is estimated to metabolize up to 20% to 30% of commonly prescribed drugs. The crystal structure was solved once again through heterogenous expression of a soluble recombinant CYP2D6 in *E. coli* utilizing a pCWOri+ derived vector (Rowland et al., 2006) (Table 1). This experiment revealed a structure most closely resembling that of CYP2C9, and the crystallography data enabled further research efforts toward building a more detailed understanding of the structural basis of ligand binding and specificity (Rowland et al., 2006). This information proved especially critical in understanding the many biotransformations mediated by CYP2D6 and CYP2C9, as their allelic variants between ethnic groups and polymorphisms between individuals can have a dramatic effect on metabolic activity, drug disposition, and therapeutic outcomes (Higashi et al., 2002; Yu et al., 2002; Ingelman-Sundberg, 2005; Zhou, 2009a,b). The rDNA platform has been adapted to interrogate the impact of specific CYP polymorphisms present in the population, uncovering mechanistic rationale for unique phenotypes of drug metabolism. The ability to recombinantly express specific P450 polymorphisms has allowed researchers to quantify enzymatic differences in the presence of any substrate, providing critical knowledge in our understanding of pharmacogenomic variability between individuals and populations. This knowledge has proven invaluable in drug design and clinical practice, as CYP polymorphisms and genetic variants can result in altered ADME processes, DDIs, and unexpected adverse effects. One key example of this is observed in warfarin-treated individuals with CYP2C9 polymorphisms, who are at increased risk of major bleeding events and excessive anticoagulation associated with increased drug exposure (Higashi et al., 2002). CYP2C9 polymorphisms have also been shown to promote genotype-dependent DDIs when warfarin or other major substrates are coadministered with an inducer or inhibitor of CYP2C9 (Higashi et al., 2002; Gardin et al., 2019; Cheng et al., 2022). Research utilizing rDNA technologies has revealed many genotype-specific differences in PK function and individual drug disposition, providing understanding that is critical to rational drug design, clinical dose management, and DDI prediction. Elucidating these pharmacogenomic differences has been key in developing and maintaining safe therapies, and this knowledge will prove increasingly useful as pharmacogenomic testing of patients becomes more commonplace and cost effective (Goh et al., 2017; Sayer et al., 2021).

In addition to providing valuable insight into the most predominant drug metabolizing P450s, rDNA technologies have also been used to characterize P450 enzymes that biosynthesize critical endogenous compounds. One predominant example of this is human CYP17A1, which is known to catalyze the synthesis of androgens and other important steroids (Miller and Auchus, 2011). Because of this, CYP17A1 inhibition represents an attractive strategy to prevent androgen synthesis and treat castration-resistant prostate cancer. The crystal structures of CYP17A1 bound to two inhibitors were determined by recombinant expression of a truncated in version in *E. coli* (DeVore and Scott, 2012) (Table 1). These initial findings elucidated the structural features integral to CYP17A1's catalytic activity, further enhanced soon afterward by crystal structures of CYP17A1 with all four of its major endogenous substrates and clinically relevant inhibitors (Petrunak et al., 2014, 2017). Structural characterization of CYP17A1 enabled by recombinant expression provided critical information in the rational drug design of CYP17A1 inhibitors. Additionally, rDNA technologies allowed investigators to develop more selective CYP17A1 inhibitors through assessment of off-target interactions with other steroidogenic P450 enzymes such as CYP21A2 (Fehl et al., 2018).

Another enzyme that mediates critical biosynthetic reactions is cytochrome P450 aromatase (CYP19A1), which is known to synthesize estrogens from androgens. While the crystal structure of CYP19A1 was first determined using aromatase purified from human placenta, subsequent research efforts recombinantly expressed truncated CYP19A1 to further its structural characterization and interrogate the functional roles of specific amino acid residues (Ghosh et al., 2009, 2010; Lo et al., 2013) (Table 1). This insight into the structure of CYP19A1 and its androgen-specific active site aided the intelligent design of aromatase inhibitor drugs used to treat hormone receptor-positive breast cancers (Ghosh et al., 2012). Indeed, this same approach has proven similarly useful in the characterization of many P450 enzymes that catalyze the biosynthesis of important endogenous compounds (Brixius-Anderko and Scott, 2019, 2021; Liu et al., 2022). These investigations have supported the rational design of selective inhibitor drugs, with recent examples being the characterizations of P450 11B1, P450 11B2, and P450 8B1, which catalyze the production of cortisol, aldosterone, and bile acid, respectively (Brixius-Anderko and Scott, 2019, 2021; Liu et al., 2022) (Table 1).

### Recombinant RNAs for Studying ADME Gene Regulation

New advancements in epigenetics in DMPK as well as ADME gene regulation and function are critical in designing the next generation of safe and effective therapeutics. One of the most important factors in the posttranscriptional regulation of ADME genes are the aforementioned miRNAs, whose wide range of regulatory targets and functions allow them to drive therapy resistance or sensitivity depending on the nature of miRNA, disease, and context (Liu et al., 2015; Mognato and Celotti, 2015; O'Brien et al., 2018; Li et al., 2019). As discussed earlier, successes in recombinant technologies have also provided scientists with the tools to produce biologic RNA molecules as research tools and potential therapeutics. To this end, the Yu laboratory has established a novel approach to generate recombinant or bioengineered RNA (BioRNA) molecules in high yield utilizing *E. coli* fermentation (Li et al., 2021; Tu et al., 2021) (Fig. 3). These BioRNAs synthesized and processed inside living cells more accurately represent the properties and chemical modifications of endogenous miRNAs compared with commercially available chemical mimics (Ho and Yu, 2016; Yu et al., 2019). This approach has been used to generate a collection of humanized miRNAs more representative of their natural state, allowing for more accurate interrogation of their epigenetic regulation of ADME genes to influence drug disposition and therapeutic outcomes (Yu et al., 2019; Tu et al., 2021).


To bioengineer these RNA molecules in *E. coli*, the pBSTNAV vector is used to accomplish cloning and expression. This vector contains an ampicillin resistance gene, compatible ColE1 and pBR322 ori sites, a strong lipoprotein promoter, and a ribosomal RNA operon termination sequence (*rrnC*) (Fig. 3) (Ponchon et al., 2009; Tu et al., 2021). These features allow for antibiotic-based selection of positive transformants and enable cloning and expression of a noncoding RNA (ncRNA) segment within the plasmid (Sutcliffe, 1978). This is accomplished using a gene insert encoding a fused transfer RNA (tRNA)/pre-miRNA carrier molecule that can be stably expressed in *E. coli* (Li et al., 2021) (Fig. 3). The identity of the tRNA and pre-miRNA sequences influence expression efficiency, and research efforts investigating different tRNA scaffolds and pre-miRNA species have resulted in an optimized stable carrier system capable of consistently expressing BioRNAs at levels surpassing 30% of total bacterial RNA (Ho et al., 2018; Tu et al., 2021). This stable hybrid carrier has been refined to achieve production at high yield, with human tRNA fused hsa-pre-miR-34a demonstrating consistently high expression with many different ncRNA cargos (Li et al., 2021). Within a

stable human tRNA/hsa-pre-miR34a carrier, the miR-34a duplex can be replaced with payload miRNA sequences of interest to generate recombinant miRNA agents (Fig. 3) (Tu et al., 2021). This duplex can also be replaced with other small RNAs such as siRNA or even multiple payload RNA sequences, highlighting the flexibility of this approach (Petrek et al., 2019).

Through these research efforts, the Yu laboratory has developed a robust bioengineering platform capable of producing humanized BioRNAs in high yield to investigate their role in the posttranscriptional regulation of ADME genes as well as their impact on therapeutic susceptibility and treatment outcomes. Websites such as miRBase, miRDB, and Targetscan are valuable resources in identifying ncRNA segments of interest as well as investigating gene transcripts that are predicted regulatory targets of specific miRNA sequences. Sequences encoding target BioRNAs are modified with appropriate cloning sites for vector insertion and amplified by polymerase chain reaction utilizing forward and reverse cloning primers with 15 nucleotide overlaps (Li et al., 2021; Tu et al., 2021). Amplified BioRNA segments are then ligated into the pBSTNAV plasmid following linearization with the restriction enzymes EcoRI and PstI, with strategies utilizing EagI and SacII being used to some success in the past (Li et al., 2021; Tu et al., 2021) (Fig. 3). Plasmids containing target BioRNA inserts are confirmed by sequencing analyses and used to transform HST08 competent *E. coli* cells to achieve overexpression of rRNAs (Li et al., 2021; Tu et al., 2021). Total RNA is then isolated from bacterial culture, and successful expression of target BioRNA is verified through the appearance of a strong band of expected size on an acrylamide-urea gel (Tu et al., 2021). Anion exchange fast protein liquid chromatography is used to separate the RNAs, allowing the collection of fractions containing the target BioRNA (Tu et al., 2021). These fractions can be run on a gel to determine their purity in a semiquantitative manner, with the purest of these being pooled together to undergo desalting and concentration procedures. These isolated BioRNAs then have their purity quantitatively assessed by high performance liquid chromatography, and the level of bacterial endotoxin within each is determined (Tu et al., 2021).

The streamlined procedure outlined here in brief has been used to express and purify a collection of humanized BioRNA agents for use in research. These BioRNAs serve as prodrugs for the warhead miRNAs they contain, being processed by endogenous machinery to generate high levels of target miRNAs as detectable by stem-loop reverse transcription-quantitative polymerase chain reaction or RNA sequencing (Li et al., 2021). Selective processing of bioengineered miRNA prodrugs to their target miRNAs has been demonstrated in several in vitro and mouse models, as well as their ability to regulate gene expression to impact cellular processes and chemosensitivities (Ho et al., 2018; Jilek et al., 2019; Li et al., 2021) (Table 2). This innovative platform has been leveraged to investigate the therapeutic potential and epigenetic role of many small RNAs across several disease states and target protein types. In the remainder of this review, we highlight several recent studies utilizing these strategies to interrogate miRNA's role in the posttranscriptional regulation of gene products integral to drug metabolism and disposition (Table 2).

The first investigation utilizing recombinant miRNAs to modulate ADME gene expression was published in 2014, and this study only used a tRNA scaffold to achieve expression of hsa-pre-miR-27b (Li et al., 2014). Previous research had shown miR-27b to be a negative regulator of CYP3A4 and vitamin D receptor (VDR) through targeting the 3'-untranslated regions of these transcripts (Pan et al., 2009), making miR-27b an ideal choice to test the effectiveness of recombinant miRNA molecules in accomplishing target gene regulation. The VDR is a nuclear receptor that is known to play a critical role in the transcriptional control of CYP3A4 (Qin and Wang, 2019). The tRNA fused to hsa-pre-miR-27b was successfully expressed in *E. coli* but demonstrated low overall



**Fig. 3.** Design of recombinant RNA expression plasmids for fermentation production in *E. coli*. (A) Recombinant or BioRNA agents are expressed with hybrid tRNA/pre-miRNA carriers, protecting them from RNase degradation and generating consistently high yield of desired BioRNA from bacterial culture. The miR-34a duplex highlighted in red can be replaced with a payload ncRNA of interest to be recombinantly expressed as part of this hybrid carrier. (B) An expression vector derived from the pBSTNAV plasmid is used for recombinant BioRNA expression. This vector contains a strong lipoprotein gene promoter as well as a ribosomal RNA operon transcription terminator (*rrnC*) to ensure efficient expression of the BioRNA insert. This vector also contains *ColE1* and *F1 ori* sites, which are recognized by *E. coli* and M13 bacteriophages, respectively. The gene encoding ampicillin resistance (*Amp<sup>R</sup>*) is also present in the vector, which enables positive selection of positive transformants through antibiotic treatment. (C) Payload ncRNA is identified and the resulting BioRNA sequence is defined accordingly. Restriction sites are added to the ends of the BioRNA coding sequence, and cloning primers are designed to replace mature miR-34a-5p and its complementary strand with the desired payload ncRNA. This BioRNA insert is then amplified by polymerase chain reaction in preparation for vector insertion. The vector is then linearized by endonucleases *EcoRI* and *PstI*, allowing insertion and ligation of the recombinant BioRNA gene insert. Once verified, the BioRNA expression plasmid is then ready for transformation into HST08 *E. coli* for recombinant BioRNA expression.

abundance with recombinant RNA making up only 2% of total bacterial RNA (Li et al., 2014). Despite this challenge, tRNA/hsa-pre-miR-27b was successfully purified from bacteria and transfected into human cells for further study. The recombinant RNA was successfully processed to

mature miR-27b in LS180 cells, and further analysis demonstrated the suppression of CYP3A4 and VDR protein expression as well as mRNA transcript abundance (Li et al., 2014). This reduced protein expression also corresponded with a decrease in CYP3A4 enzymatic activity,

TABLE 2  
Modulation of ADME gene expression as well as drug metabolism and transport by recombinant RNA agents

BioRNA	ADME gene	Effects	References
miR-27b-3p	CYP3A4	Downregulates CYP3A4 mRNA transcript abundance, protein expression, and 1'-hydroxylase activity in LS180 cells	Li et al., 2014; Li et al., 2019
miR-1291-5p	ABCC1	Downregulates ABCC1 protein expression in MCF-7 and PANC-1 cells and sensitizes them to doxorubicin treatment	Li et al., 2015
miR-124-3p	ABCC4	Downregulates ABCC4 and STAT3 protein expression in A549	Ho et al., 2018
miR-328-3p	ABCG2	Downregulates ABCG2/BCRP mRNA transcript abundance and protein expression in MCF7/MX100 cells to increase intracellular accumulation of mitoxantrone and sensitize cells to treatment	Li et al., 2019
let-7c-5p	ABCC5 ABCC4	Downregulates ABCC5 and ABCC4 protein expression in Huh7 cells, promotes intracellular accumulation of 5-FU, and exhibits synergistic effects inhibiting Huh7 cell viability	Jilek et al., 2020

BCRP, breast cancer resistance protein; 5-FU, fluorouracil.

demonstrated by a reduced capacity to perform the 1'-hydroxylation of probe drug midazolam (Li et al., 2014). In 2015, this same strategy was used to produce recombinant tRNA/hsa-pre-miR-1291 for functional study in human carcinoma cells (Li et al., 2015). This chimeric RNA was processed to mature miR-1291 in MCF-7 and PANC-1 cell lines, where it was able to effectively downregulate the protein expression of target ABCC1 (Li et al., 2015) (Table 2). Overexpression of ABCC1 and similar transporters is a common occurrence in cancers, which is believed to contribute to therapeutic evasion and multidrug resistance. Introduction of recombinant tRNA/hsa-pre-miR-1291 into PANC-1 cells also enhanced their sensitivity to doxorubicin, a known substrate of the ABCC1 transporter (Li et al., 2015). These results highlighted the early potential of recombinant miRNAs in modulating ADME gene expression to alter drug exposure, overcome resistance, and improve therapeutic outcomes.

The identification and use of a stable tRNA/pre-miRNA carrier to produce functional small RNA agents was first reported in 2015, as most target RNAs cannot be heterogeneously expressed with a tRNA scaffold alone (Chen et al., 2015). A few years later in 2018, another research paper was published that optimized the use of the discussed hybrid tRNA/pre-miRNA carrier to achieve substantially higher yields of target ncRNA sequences from bacterial fermentation, with a greater success rate (Ho et al., 2018). Utilizing this approach, recombinant miR-124 was generated and used to transfect human cells. The administered agent was then selectively processed to miR-124-3p within the cells, effectively downregulating its established targets ABCC4, as well as other cancer-related genes, and inhibiting proliferation of carcinoma cells (Ho et al., 2018) (Table 2). Further research in 2019 used these innovations in the tRNA/pre-miR-34a carrier to generate BioRNA/miR-27b-3p (Li et al., 2019) (Table 2), which was much more highly expressed in *E. coli* compared with when it was produced with only a tRNA carrier (Li et al., 2014). Once administered to LS-180 cells, BioRNA/miR-27b-3p was processed to mature miR-27b-3p and again successfully suppressed expression of its targets CYP3A4 and VDR. This once again corresponded with a reduction in enzyme activity as demonstrated by a decrease in midazolam 1'-hydroxylase metabolism (Li et al., 2019). This study also produced BioRNA/miR-328-3p for functional study, and it was selectively processed to mature miR-328-3p in human lung carcinoma cells. MiR-328-3p is a known regulatory miRNA for ABCG2, which is a critical drug transporter implicated in chemotherapeutic resistance that is also commonly known as breast cancer resistance protein (Li et al., 2011). Transfection with BioRNA/miR-328-3p resulted in knockdown of ABCG2 protein levels and mRNA transcripts, sensitizing chemo-resistant MCF7/MX100 cells to mitoxantrone treatment via promoting the drug's intracellular accumulation (Li et al., 2019) (Table 2). Mitoxantrone is an established substrate of ABCG2, providing an explanation as to why downregulation of this transporter could sensitize cancer cells to treatment. Intracellular accumulation of the drug was

assessed by examining mitoxantrone fluorescence intensity, which was higher across BioRNA/miR-328-3p treated cells (Li et al., 2019).

Another study published in 2020 investigated the role of epigenetic role of BioRNA/let-7c-5p, an agent with demonstrated promise in inhibiting hepatocellular carcinoma growth (Jilek et al., 2019, 2020). This BioRNA was processed to mature let-7c-5p within living cells, effectively suppressing the protein levels of ABCC4 and ABCC5 transporters (Jilek et al., 2020) (Table 2). Downregulation of these transporters by BioRNA/let-7c-5p promoted intracellular accumulation of cancer drug 5-FU, explaining the synergistic effects observed with these agents in the inhibition of cancer cell viability (Jilek et al., 2020). While most ADME research utilizing this platform so far has been centered on miRNAs, it has also been used to elucidate the epigenetic role of nuclear factor erythroid 2-related factor 2 (NRF2) through a corresponding siRNA. NRF2 is a transcription factor understood to play a critical role in the induction of ADME gene products such as ABC transporters, with NRF2 overexpression being a commonly observed phenomenon in multidrug resistant cancers (Lu et al., 2016; Li et al., 2018; Hu et al., 2019). Administration of BioRNA/NRF2-siRNA resulted in significant downregulation of the transporters ABCC3, ABCC4, and ABCC5, sensitizing human cancer cells to commonly employed chemotherapeutics doxorubicin, cisplatin, and sorafenib (Li et al., 2018).

### Conclusions and Perspectives

rDNA technologies have revolutionized the field of drug metabolism and PK, equipping investigators with the tools to produce pure ADME gene products for research and development. Advancements in our understanding and utilization of expression vectors and host organisms has provided researchers with a versatile and adaptable toolbox to express and purify almost any gene of interest. This strategy has been widely employed in the study of P450 monooxygenases, where heterologous expression of these drug-metabolizing enzymes has allowed investigators to examine their conformational interactions with xenobiotics and endogenous compounds. In this way, recombinant technologies have provided novel insights into CYP enzymes and other ADME gene products, catapulting forward the fields of DMPK. These research efforts have armed investigators with critical understanding of the molecular mechanisms underlying xenobiotic biotransformation and disposition, providing information that is invaluable to the development of safe and effective therapeutics. Recombinant protein expression continues to hold incredible potential for future DMPK research, improving availability of robust research tools in addition to aiding the design of new antibodies and specific inhibitor drugs by providing facile means to express and purify specific transgenes of interest.

As recombinant technologies have granted us further insight into the gene products behind DMPK processes, they have also revealed an

increasingly complex picture of drug metabolism that can vary widely between populations and individuals. Keeping this in mind, it is essential that investigators continue to employ rDNA technologies in new and innovative ways to interrogate the function and regulation of ADME gene products. Recently, miRNAs have emerged as important factors in this equation, with their roles in posttranscriptional regulation of ADME genes having a significant impact on drug metabolism and transport as well as PK and efficacy (Yu et al., 2016; Jilek et al., 2017). To build upon our understanding of miRNA-directed regulation and address the widespread usage of synthetic miRNA mimics in research, an innovative bioengineering platform has been developed, capable of generating tens milligram quantities of pure recombinant RNA agents from only a liter of bacterial culture. These humanized BioRNA agents are produced and processed inside living cells, serving as a more accurate representation of natural endogenous miRNAs. These BioRNAs do not require added chemical modifications to maintain their intracellular stability. It has been proven these biologic RNA agents are selectively processed to the target miRNAs or siRNAs in human cells to selectively regulate target gene expression. Additionally, the hybrid tRNA/pre-miRNA carrier used in this technology can achieve high levels of expression with a wide variety of small RNAs (Yu and Tu, 2022; Traber and Yu, 2023). Using this novel platform, the Yu laboratory has amassed a collection of humanized BioRNA agents so that their utilities in modulating ADME gene expression may be interrogated. This novel bioengineering strategy has been successfully used in the study of several ADME genes, effectively regulating expression of targets such as P450 enzymes and ABC transporters to alter drug metabolism, transport, exposure, and therapeutic outcome. The BioRNA platform has greatly increased the quality, adaptability, and availability of miRNA research tools, making it a unique and valuable addition to DMPK research as well as rDNA technologies as a whole.

#### Authorship Contributions

Performed data analyses: Cronin, Yu.

Wrote and contributed to the writing and revision of the manuscript: Cronin, Yu.

#### References

- Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, and Song SJ (2020) Regulatory mechanism of microRNA expression in cancer. *Int J Mol Sci* **21**:1723.
- Arnold FH (2018) Directed evolution: bringing new chemistry to life. *Angew Chem Int Ed Engl* **57**:4143–4148.
- Balbás P, Soberón X, Merino E, Zurita M, Lomeli H, Valle F, Flores N, and Bolívar F (1986) Plasmid vector pBR322 and its special-purpose derivatives—a review. *Gene* **50**:3–40.
- Banner DW, Kokkinidis M, and Tsemoglou D (1987) Structure of the ColE1 rop protein at 1.7 Å resolution. *J Mol Biol* **196**:657–675.
- Barnes HJ, Arlotto MP, and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in *Escherichia coli*. *Proc Natl Acad Sci USA* **88**:5597–5601.
- Basu K, Green EM, Cheng Y, and Craik CS (2019) Why recombinant antibodies—benefits and applications. *Curr Opin Biotechnol* **60**:153–158.
- Bellamine A, Mangla AT, Nes WD, and Waterman MR (1999) Characterization and catalytic properties of the sterol 14alpha-demethylase from *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* **96**:8937–8942.
- Black SD and Coon MJ (1987) P-450 cytochromes: structure and function, in *Advances in Enzymology and Related Areas of Molecular Biology* (Meister A, ed), 35–87, John Wiley, New York.
- Bolívar F, Rodríguez RL, Betlach MC, and Boyer HW (1977a) Construction and characterization of new cloning vehicles. I. Ampicillin-resistant derivatives of the plasmid pMB9. *Gene* **2**:75–93.
- Bolívar F, Rodríguez RL, Greene PJ, Betlach MC, Heyneker HL, Boyer HW, Crosa JH, and Falkow S (1977b) Construction and characterization of new cloning vehicles. II. A multi-purpose cloning system. *Gene* **2**:95–113.
- Boylan JB, Home HH, and Johnson WJ (1963) Teratogenic effects of thalidomide and related substances. *Lancet* **1**:552.
- Brandenburg OF, Fasan R, and Arnold FH (2017) Exploiting and engineering hemoproteins for abiobiotic carbene and nitrene transfer reactions. *Curr Opin Biotechnol* **47**:102–111.
- Brixius-Anderko S and Scott EE (2019) Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design. *J Biol Chem* **294**:453–460.
- Brixius-Anderko S and Scott EE (2021) Aldosterone synthase structure with Cushing disease drug LC1699 highlights avenues for selective CYP11B drug design. *Hypertension* **78**:751–759.
- Cesarani G, Muesing MA, and Polisky B (1982) Control of ColE1 DNA replication: the rop gene product negatively affects transcription from the replication primer promoter. *Proc Natl Acad Sci USA* **79**:6313–6317.
- Chen QX, Wang WP, Zeng S, Urayama S, and Yu AM (2015) A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. *Nucleic Acids Res* **43**:3857–3869.
- Chen R (2012) Bacterial expression systems for recombinant protein production: *E. coli* and beyond. *Biotechnol Adv* **30**:1102–1107.
- Cheng S, Flora DR, Rettie AE, Brundage RC, and Tracy TS (2022) Pharmacokinetic modeling of warfarin I—model-based analysis of warfarin enantiomers with a target mediated drug disposition model reveals CYP2C9 genotype-dependent drug-drug interactions of S-warfarin. *Drug Metab Dispos* **50**:1287–1301.
- Cohen SN, Chang ACY, Boyer HW, and Helling RB (1973) Construction of biologically functional bacterial plasmids *in vitro*. *Proc Natl Acad Sci USA* **70**:3240–3244.
- Coon MJ (2005) Cytochrome P450: nature's most versatile biological catalyst. *Annu Rev Pharmacol Toxicol* **45**:1–25.
- Cox MH, Kapoor P, Briggs DA, and Kerr ID (2018) Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets. *Biochem J* **475**:1553–1567.
- del Solar G and Espinosa M (2000) Plasmid copy number control: an ever-growing story. *Mol Microbiol* **37**:492–500.
- del Solar G, Giraldo R, Ruiz-Echevarría MJ, Espinosa M, and Díaz-Orejón R (1998) Replication and control of circular bacterial plasmids. *Microbiol Mol Biol Rev* **62**:434–464.
- DeVore NM and Scott EE (2012) Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. *Nature* **482**:116–119.
- Dickins M (2004) Induction of cytochromes P450. *Curr Top Med Chem* **4**:1745–1766.
- Diener C, Keller A, and Meese E (2022) Emerging concepts of miRNA therapeutics: from cells to clinic. *Trends Genet* **38**:613–626.
- Dorr CR, Rimmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS et al. (2017) CRISPR/Cas9 genetic modification of CYP3A5 \*3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism. *Drug Metab Dispos* **45**:957–965.
- Doudna JA (2020) The promise and challenge of therapeutic genome editing. *Nature* **578**:229–236.
- Estabrook RW (2003) A passion for P450s (remembrances of the early history of research on cytochrome P450). *Drug Metab Dispos* **31**:1461–1473.
- Fehl C, Vogt CD, Yadav R, Li K, Scott EE, and Aubé J (2018) Structure-based design of inhibitors with improved selectivity for steroidogenic cytochrome P450 17A1 over cytochrome P450 21A2. *J Med Chem* **61**:4946–4960.
- Food and Drug Administration (FDA) (2021) Fact Sheet: FDA at a Glance <https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance>.
- Fothergill-Gilmore LA (1993) *Protein Biotechnology: Isolation, Characterization, and Stabilization*, Humana Press, Totowa, NJ.
- Friehs K (2004) Plasmid copy number and plasmid stability, in *New Trends and Developments in Biochemical Engineering* (Scheper T ed) pp 47–82, Springer, Berlin.
- Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, Pal P, Li W, and Shakeri-Nejad K (2019) Effect of fluconazole coadministration and CYP2C9 genetic polymorphism on sipinomid pharmacokinetics in healthy subjects. *Clin Pharmacokinet* **58**:349–361.
- Gasnov NB, Toshchakov SV, Georgiev PG, and Maksimenko OG (2015) The use of transcription terminators to generate transgenic lines of Chinese hamster ovary cells (CHO) with stable and high level of reporter gene expression. *Acta Naturae* **7**:74–80.
- Ghosh D, Griswold J, Erman M, and Pangborn W (2009) Structural basis for androgen specificity and oestrogen synthesis in human aromatase. *Nature* **457**:219–223.
- Ghosh D, Griswold J, Erman M, and Pangborn W (2010) X-ray structure of human aromatase reveals an androgen-specific active site. *J Steroid Biochem Mol Biol* **118**:197–202.
- Ghosh D, Lo J, Morton D, Valette D, Xi J, Griswold J, Hubbell S, Egbuta C, Jiang W, An J et al. (2012) Novel aromatase inhibitors by structure-guided design. *J Med Chem* **55**:8464–8476.
- Giver L, Gershenson A, Freskgard PO, and Arnold FH (1998) Directed evolution of a thermostable esterase. *Proc Natl Acad Sci USA* **95**:12809–12813.
- Goeddel DV, Kleid DG, Bolívar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, and Riggs AD (1979) Expression in *Escherichia coli* of chemically synthesized genes for human insulin. *Proc Natl Acad Sci USA* **76**:106–110.
- Goh LL, Lim CW, Sim WC, Toh LX, and Leong KP (2017) Analysis of genetic variation in CYP450 genes for clinical implementation. *PLoS One* **12**:e0169233.
- Gonzalez FJ and Gelboin HV (1992) Human cytochromes P450: evolution and cDNA-directed expression. *Environ Health Perspect* **98**:81–85.
- Gonzalez FJ, Schmid BJ, Umeno M, Mcbride OW, Hardwick JP, Meyer UA, Gelboin HV, and Idle JR (1988a) Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. *DNA* **7**:79–86.
- Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, and Meyer UA (1988b) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. *Nature* **331**:442–446.
- Gonzalez FJ and Yu AM (2006) Cytochrome P450 and xenobiotic receptor humanized mice. *Annu Rev Pharmacol Toxicol* **46**:41–64.
- Gordon GB, Spielberg SP, Blake DA, and Balasubramanian V (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. *Proc Natl Acad Sci USA* **78**:2545–2548.
- Graham MJ and Lake BG (2008) Induction of drug metabolism: species differences and toxicological relevance. *Toxicology* **254**:184–191.
- Guengerich FP (1977) Separation and purification of multiple forms of microsomal cytochrome P-450. Activities of different forms of cytochrome P-450 towards several compounds of environmental interest. *J Biol Chem* **252**:3970–3979.
- Guengerich FP (2020) A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. *Toxicol Res* **37**:1–23.
- Gunsalus IC and Wagner GC. (1978) [17] Bacterial P-450cam methylene monooxygenase components: cytochrome m, putidaredoxin, and putidaredoxin reductase, in *Methods in Enzymology* (Fleischer S and Packer L eds) pp 166–188, Academic Press, New York.
- Guo LQ and Yamazoe Y (2004) Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. *Acta Pharmacol Sin* **25**:129–136.
- Haugen DA, van der Hoeven TA, and Coon MJ (1975) Purified liver microsomal cytochrome P-450. Separation and characterization of multiple forms. *J Biol Chem* **250**:3567–3570.
- Helmer-Citterich M, Anneschi MM, Banner DW, and Cesarani G (1988) Control of ColE1 replication: low affinity specific binding of Rop (Rom) to RNAI and RNAII. *EMBO J* **7**:557–566.

- Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, and Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA* **287**:1690–1698.
- Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, Kobayashi K, Chiba K, Nanba E, Oshimura M, Sato T et al. (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. *Hum Mol Genet* **13**:2959–2969.
- Hiruma Y, Hass MA, Kikui Y, Liu WM, Ölzem B, Skinner SP, Blok A, Kloosterman A, Koteishi H, Löhr F et al. (2013) The structure of the cytochrome p450cam-putidaredoxin complex determined by paramagnetic NMR spectroscopy and crystallography. *J Mol Biol* **425**:4353–4365.
- Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW et al. (2018) Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy. *J Pharmacol Exp Ther* **365**:494–506.
- Ho PY and Yu AM (2016) Bioengineering of noncoding RNAs for research agents and therapeutics. *Wiley Interdiscip Rev RNA* **7**:186–197.
- Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang JJ, Ieiri I, Lee JE et al. (2017) Characterization of ADME gene variation in 21 populations by exome sequencing. *Pharmacogenet Genomics* **27**:89–100.
- Hsu MH, Griffin KJ, Wang Y, Kemper B, and Johnson EF (1993) A single amino acid substitution confers progesterone 6 beta-hydroxylase activity to rabbit cytochrome P450 2C3. *J Biol Chem* **268**:6939–6944.
- Hsu MH, Savas U, and Johnson EF (2018) The X-ray crystal structure of the human mono-oxygenase cytochrome P450 3A5-ritonavir complex reveals active site differences between P450s 3A4 and 3A5. *Mol Pharmacol* **93**:14–24.
- Hu J, Tian J, Zhang F, Wang H, and Yin J (2019) Pxr- and Nrf2- mediated induction of ABC transporters by heavy metal ions in zebrafish embryos. *Environ Pollut* **255**:113329.
- Hutchinson 3rd CA, Phillips S, Edgell MH, Gillam S, Jahnke P, and Smith M (1978) Mutagenesis at a specific position in a DNA sequence. *J Biol Chem* **253**:6551–6560.
- Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, and Kesselheim AS (2016) Failure of investigational drugs in late-stage clinical development and publication of trial results. *JAMA Intern Med* **176**:1826–1833.
- Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics* **5**:6–13.
- Itakura K, Hirose T, Crea R, Riggs AD, Heyneker HL, Bolivar F, and Boyer HW (1977) Expression in *Escherichia coli* of a chemically synthesized gene for the hormone somatostatin. *Science* **198**:1056–1063.
- Jilek JL, Tian Y, and Yu AM (2017) Effects of microRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice. *Drug Metab Dispos* **45**:512–522.
- Jilek JL, Tu MJ, Zhang C, and Yu AM (2020) Pharmacokinetic and pharmacodynamic factors contribute to synergism between Let-7c-5p and 5-fluorouracil in inhibiting hepatocellular carcinoma cell viability. *Drug Metab Dispos* **48**:1257–1263.
- Jilek JL, Zhang QY, Tu MJ, Ho PY, Duan Z, Qiu JX, and Yu AM (2019) Bioengineered Let-7c inhibits orthotopic hepatocellular carcinoma and improves overall survival with minimal immunogenicity. *Mol Ther Nucleic Acids* **14**:498–508.
- Joo H, Arisawa A, Lin Z, and Arnold FH (1999) A high-throughput digital imaging screen for the discovery and directed evolution of oxygenases. *Chem Biol* **6**:699–706.
- Karakus E, Wannowius M, Müller SF, Leitung S, Leidolf R, Noppes S, Oswald S, Diener M, and Geyer J (2020) The orphan solute carrier SLC10A7 is a novel negative regulator of intracellular calcium signaling. *Sci Rep* **10**:7248.
- Karlgen M, Simoff I, Keiser M, Oswald S, and Artursson P (2018) CRISPR-Cas9: a new addition to the drug metabolism and disposition tool box. *Drug Metab Dispos* **46**:1776–1786.
- Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. *Mol Pharmacol* **61**:495–506.
- Khvorova A and Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. *Nat Biotechnol* **35**:238–248.
- Koga H, Rauchfuss B, and Gunsalus IC (1985) P450cam gene cloning and expression in *Pseudomonas putida* and *Escherichia coli*. *Biochem Biophys Res Commun* **130**:412–417.
- Larson JR, Coon MJ, and Porter TD (1991a) Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH<sub>2</sub>-terminal segment retains catalytic activity and is membrane-bound when expressed in *Escherichia coli*. *J Biol Chem* **266**:7321–7324.
- Larson JR, Coon MJ, and Porter TD (1991b) Purification and properties of a shortened form of cytochrome P-450 2E1: deletion of the NH<sub>2</sub>-terminal membrane-insertion signal peptide does not alter the catalytic activities. *Proc Natl Acad Sci USA* **88**:9141–9145.
- Lederberg J (1952) Cell genetics and hereditary symbiosis. *Physiol Rev* **32**:403–430.
- Lee CP, Schatz G, and Dallner G (1981) *Mitochondria and Microsomes: In Honor of Lars Ernster*. Addison-Wesley, Reading, MA.
- Li H and Lampe JN (2019) Neonatal cytochrome P450 CYP3A7: a comprehensive review of its role in development, disease, and xenobiotic metabolism. *Arch Biochem Biophys* **673**:108078.
- Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, and Yu AM (2015) Chimeric microRNA-1291 biosynthesized efficiently in *Escherichia coli* is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. *Drug Metab Dispos* **43**:1129–1136.
- Li MM, Wang WP, Wu WJ, Huang M, and Yu AM (2014) Rapid production of novel pre-microRNA agent hsa-mir-27b in *Escherichia coli* using recombinant RNA technology for functional studies in mammalian cells. *Drug Metab Dispos* **42**:1791–1795.
- Li PC, Tu MJ, Ho PY, Batra N, Tran MML, Qiu JX, Wun T, Lara PN, Hu X, Yu AX et al. (2021) *In vivo* fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy. *Theranostics* **11**:4858–4871.
- Li PC, Tu MJ, Ho PY, Jilek JL, Duan Z, Zhang QY, Yu AX, and Yu AM (2018) Bioengineered NRF2-siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells. *Drug Metab Dispos* **46**:2–10.
- Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, and Yu AM (2011) Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. *Biochem Pharmacol* **81**:783–792.
- Li X, Tian Y, Tu MJ, Ho PY, Batra N, and Yu AM (2019) Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. *Acta Pharm Sin B* **9**:639–647.
- Li Y, Glass Z, Huang M, Chen ZY, and Xu Q (2020) Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. *Biomaterials* **234**:119711.
- Li YC and Chiang JY (1991) The expression of a catalytically active cholesterol 7 alpha-hydroxylase cytochrome P450 in *Escherichia coli*. *J Biol Chem* **266**:19186–19191.
- Liang C, Zhao J, Lu J, Zhang Y, Ma X, Shang X, Li Y, Ma X, Liu M, and Wang X (2019) Development and characterization of MDR1 (*Mdr1a/b*) CRISPR/Cas9 knockout rat model. *Drug Metab Dispos* **47**:71–79.
- Liu H, Wu X, Huang J, Peng J, and Guo L (2015) miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. *Int J Exp Pathol* **96**:240–247.
- Liu J, Carlson HA, and Scott EE (2022) The structure and characterization of human cytochrome P450 8B1 supports future drug design for nonalcoholic fatty liver disease and diabetes. *J Biol Chem* **298**:102344.
- Lo J, Di Nardo G, Griswold J, Egbuta C, Jiang W, Gilardi G, and Ghosh D (2013) Structural basis for the functional roles of critical residues in human cytochrome p450 aromatase. *Biochemistry* **52**:5821–5829.
- Lu AY, Strobel HW, and Coon MJ (1969) Hydroxylation of benzphetamine and other drugs by a solubilized form of cytochrome P-450 from liver microsomes: lipid requirement for drug demethylation. *Biochem Biophys Res Commun* **36**:545–551.
- Lu AYH and Coon MJ (1968) Role of hemoprotein P-450 in fatty acid  $\omega$ -hydroxylation in a soluble enzyme system from liver microsomes. *J Biol Chem* **243**:1331–1332.
- Lu BC, Li J, Yu WF, Zhang GZ, Wang HM, and Ma HM (2016) Elevated expression of Nrf2 mediates multidrug resistance in CD133<sup>+</sup> head and neck squamous cell carcinoma stem cells. *Oncol Lett* **12**:4333–4338.
- Lu J, Liu J, Guo Y, Zhang Y, Xu Y, and Wang X (2021) CRISPR-Cas9: a method for establishing rat models of drug metabolism and pharmacokinetics. *Acta Pharm Sin B* **11**:2973–2982.
- Maniatis T, Fritsch EF, and Sambrook J (1983) *Molecular Cloning*. Cold Spring Harbor Laboratory, Lowell Harbor, NY.
- Marks JD, Hoogenboom HR, Bonnett TP, McCafferty J, Griffiths AD, and Winter G (1991) Bypassing immunization. Human antibodies from V-gene libraries displayed on phage. *J Mol Biol* **222**:581–597.
- Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. *Expert Opin Drug Metab Toxicol* **2**:875–894.
- McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, Erlandson SC, Hilger D, Rasmussen SGF, Ring AM et al. (2018) Yeast surface display platform for rapid discovery of conformationally selective nanobodies. *Nat Struct Mol Biol* **25**:289–296.
- Mendel G (1865) Versuche über pflanzen-hybriden. *Verhandlungen des naturforschenden Vereines in Brünn* **4**:3–47.
- Miller WL and Auchus RJ (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev* **32**:81–151.
- Mognato M and Celotti L (2015) MicroRNAs used in combination with anti-cancer treatments can enhance therapy efficacy. *Mini Rev Med Chem* **15**:1052–1062.
- Morris ZS, Wooding S, and Grant J (2011) The answer is 17 years, what is the question: understanding time lags in translational research. *J R Soc Med* **104**:510–520.
- Morrow JF, Cohen SN, Chang AC, Boyer HW, Goodman HM, and Helling RB (1974) Replication and transcription of eukaryotic DNA in *Escherichia coli*. *Proc Natl Acad Sci USA* **71**:1743–1747.
- Nakamura K, Goto F, Ray WA, McAllister CB, Jaczq E, Wilkinson GR, and Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. *Clin Pharmacol Ther* **38**:402–408.
- Negishi M, Swan DC, Enquist LW, and Nebert DW (1981) Isolation and characterization of a cloned DNA sequence associated with the murine Ah locus and a 3-methylcholanthrene-induced form of cytochrome P-450. *Proc Natl Acad Sci USA* **78**:800–804.
- O'Brien J, Hayder H, Zayed Y, and Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Front Endocrinol (Lausanne)* **9**:402.
- Oeda K, Sakaki T, and Ohkawa H (1985) Expression of rat liver cytochrome P-450MC cDNA in *Saccharomyces cerevisiae*. *DNA* **4**:203–210.
- Omura T and Sato R (1962) A new cytochrome in liver microsomes. *J Biol Chem* **237**:1375–1376.
- Öztürk S, Ergün BG, and Çalök P (2017) Double promoter expression systems for recombinant protein production by industrial microorganisms. *Appl Microbiol Biotechnol* **101**:7459–7475.
- Pan YZ, Gao W, and Yu AM (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. *Drug Metab Dispos* **37**:2112–2117.
- Patil N, Sivaram A, Modak M, and Nyayanit N (2022) *A Complete Guide to Gene Cloning: From Basic to Advanced*. Springer, Cham, Switzerland.
- Petek H, Batra N, Ho PY, Tu MJ, and Yu AM (2019) Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs. *Appl Microbiol Biotechnol* **103**:6107–6117.
- Petrunak EM, DeVore NM, Porubsky PR, and Scott EE (2014) Structures of human steroidogenic cytochrome P450 17A1 with substrates. *J Biol Chem* **289**:32952–32964.
- Petrunak EM, Rogers SA, Aubé J, and Scott EE (2017) Structural and functional evaluation of clinically relevant inhibitors of steroidogenic cytochrome P450 17A1. *Drug Metab Dispos* **45**:635–645.
- Podust LM, Poulos TL, and Waterman MR (2001) Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from *Mycobacterium tuberculosis* in complex with azole inhibitors. *Proc Natl Acad Sci USA* **98**:3068–3073.
- Ponchon L, Beauvais G, Nonin-Lecomte S, and Dardel F (2009) A generic protocol for the expression and purification of recombinant RNA in *Escherichia coli* using a tRNA scaffold. *Nat Protoc* **4**:947–959.
- Poulos TL, Finzel BC, Gunsalus IC, Wagner GC, and Kraut J (1985) The 2.6-Å crystal structure of *Pseudomonas putida* cytochrome P-450. *J Biol Chem* **260**:16122–16130.
- Poulos TL, Finzel BC, and Howard AJ (1986) Crystal structure of substrate-free *Pseudomonas putida* cytochrome P-450. *Biochemistry* **25**:5314–5322.
- Poulos TL, Finzel BC, and Howard AJ (1987) High-resolution crystal structure of cytochrome P450cam. *J Mol Biol* **195**:687–700.
- Poulos TL and Follmer AH (2022) Updating the paradigm: redox partner binding and conformational dynamics in cytochromes P450. *Acc Chem Res* **55**:373–380.
- Poulos TL, Perez M, and Wagner GC (1982) Preliminary crystallographic data on cytochrome P-450CAM. *J Biol Chem* **257**:10427–10429.
- Qin X and Wang X (2019) Role of vitamin D receptor in the regulation of CYP3A gene expression. *Acta Pharm Sin B* **9**:1087–1098.
- Religia P, Nguyen ND, Nong QD, Matsuura T, Kato Y, and Watanabe H (2021) Mutation of the cytochrome P450 CYP360A8 gene increases sensitivity to paraquat in *Daphnia magna*. *Environ Toxicol Chem* **40**:1279–1288.

- Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, and Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in *Escherichia coli*. *Arch Biochem Biophys* **323**:87–96.
- Rocco CJ, Dennison KL, Klenchin VA, Rayment I, and Escalante-Semerena JC (2008) Construction and use of new cloning vectors for the rapid isolation of recombinant proteins from *Escherichia coli*. *Plasmid* **59**:231–237.
- Roche PA and Furuta K (2015) The ins and outs of MHC class II-mediated antigen processing and presentation. *Nat Rev Immunol* **15**:203–216.
- Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS et al. (2006) Crystal structure of human cytochrome P450 2D6. *J Biol Chem* **281**:7614–7622.
- Ryan D, Lu YH, Kawalek J, West SB, and Levin L (1975) Highly purified cytochrome P-448 and P=450 from rat liver microsomes. *Biochem Biophys Res Commun* **64**:1134–1141.
- Sakaguchi M, Mihara K, and Sato R (1984) Signal recognition particle is required for co-translational insertion of cytochrome P-450 into microsomal membranes. *Proc Natl Acad Sci USA* **81**:3361–3364.
- Sakaguchi M, Mihara K, and Sato R (1987) A short amino-terminal segment of microsomal cytochrome P-450 functions both as an insertion signal and as a stop-transfer sequence. *EMBO J* **6**:2425–2431.
- Salanga MC, Brun NR, Francolini RD, Stegeman JJ, and Goldstone JV (2020) CRISPR-Cas9-mutated pregnane X receptor (pxr) retains pregnenolone-induced expression of cyp3a65 in zebrafish (*Danio rerio*) larvae. *Toxicol Sci* **174**:51–62.
- Sayer M, Duche A, Nguyen TJT, Le M, Patel K, Vu J, Pham D, Vernick B, Beuttler R, Roosan D et al. (2021) Clinical implications of combinatorial pharmacogenomic tests based on cytochrome P450 variant selection. *Front Genet* **12**:719671.
- Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. *J Biol Chem* **283**:17227–17237.
- Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, and Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. *J Biol Chem* **279**:9497–9503.
- Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, and Stout CD (2003) An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. *Proc Natl Acad Sci USA* **100**:13196–13201.
- Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. *Arch Biochem Biophys* **395**:57–68.
- Sevrioukova IF (2021) Structural basis for the diminished ligand binding and catalytic ability of human fetal-specific CYP3A7. *Int J Mol Sci* **22**:5831.
- Speirs AL (1962) Thalidomide and congenital abnormalities. *Lancet* **1**:303–305.
- Sundhari AK, Reddy SK, Walz K, Gurumurthy CB, and Quadros RM. (2019) CRISPR-Cas technology as a tool to create animal models for biomedical research, in *Cellular and Animal Models in Human Genomics Research* (Walz K and Young JJ, eds) pp 141–153, Academic Press, New York.
- Sutcliffe JG (1978) Nucleotide sequence of the ampicillin resistance gene of *Escherichia coli* plasmid pBR322. *Proc Natl Acad Sci USA* **75**:3737–3741.
- Tang C, Lin JH, and Lu AY (2005) Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? *Drug Metab Dispos* **33**:603–613.
- Traber GM and Yu A-M (2023) RNAi-based therapeutics and novel RNA bioengineering Technologies. *J Pharmacol Exp Ther* **384**:133–154.
- Tripathi S, Li H, and Poulos TL (2013) Structural basis for effector control and redox partner recognition in cytochrome P450. *Science* **340**:1227–1230.
- Tu MJ, Wright HK, Batra N, and Yu AM (2021) Expression and purification of tRNA<sup>pre-mi</sup>-RNA-based recombinant noncoding RNAs. *Methods Mol Biol* **2323**:249–265.
- Umeno M, McBride OW, Yang CS, Gelboin HV, and Gonzalez FJ (1988) Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. *Biochemistry* **27**:9006–9013.
- Unger BP, Gunsalus IC, and Sligar SG (1986) Nucleotide sequence of the *Pseudomonas putida* cytochrome P-450cam gene and its expression in *Escherichia coli*. *J Biol Chem* **261**:1158–1163.
- Vieira J and Messing J (1982) The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. *Gene* **19**:259–268.
- von Wachenfeldt C, Richardson TH, Cosme J, and Johnson EF (1997) Microsomal P450 2C3 is expressed as a soluble dimer in *Escherichia coli* following modification of its N-terminus. *Arch Biochem Biophys* **339**:107–114.
- Wadman M (2023) FDA no longer has to require animal testing for new drugs. *Science* **379**:127–128.
- Wei Y, Yang L, Zhang X, Sui D, Wang C, Wang K, Shan M, Guo D, and Wang H (2018) Generation and characterization of a CYP2C11-null rat model by using the CRISPR/Cas9 method. *Drug Metab Dispos* **46**:525–531.
- West S and Proudfoot NJ (2009) Transcriptional termination enhances protein expression in human cells. *Mol Cell* **33**:354–364.
- Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, and Stout CD (2003) Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: evidence for multiple substrate binding modes. *Biochemistry* **42**:6370–6379.
- Wester MR, Stout CD, and Johnson EF (2002) Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. *Methods Enzymol* **357**:73–79.
- Westermann L, Neubauer B, and Köttgen M (2021) Nobel Prize 2020 in chemistry honors CRISPR: a tool for rewriting the code of life. *Pflügers Arch* **473**:1–2.
- White PC, New ML, and Dupont B (1984) Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. *Proc Natl Acad Sci USA* **81**:1986–1990.
- Wilderman PR, Gay SC, Jang HH, Zhang Q, Stout CD, and Halpert JR (2012) Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme. *FEBS J* **279**:1607–1620.
- Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. *Mol Cell* **5**:121–131.
- Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. *Science* **305**:683–686.
- Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. *Nature* **424**:464–468.
- Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. *Nat Biotechnol* **22**:1393–1398.
- Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, and Kamataki T (2005) Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. *Xenobiotica* **35**:69–83.
- Yao X-Q, Kimura N, Murakami S, and Takada S (2013) Drug uptake pathways of multidrug transporter AcrB studied by molecular simulations and site-directed mutagenesis experiments. *J Am Chem Soc* **135**:7474–7485.
- Yu A-M and Tu M-J (2022) Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. *Pharmacol Ther* **230**:107967.
- Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. *J Pharmacol Exp Ther* **303**:1291–1300.
- Yu AM, Choi YH, and Tu MJ (2020) RNA drugs and RNA targets for small molecules: principles, progress, and challenges. *Pharmacol Rev* **72**:862–898.
- Yu AM, Jian C, Yu AH, and Tu MJ (2019) RNA therapy: are we using the right molecules? *Pharmacol Ther* **196**:91–104.
- Yu AM, Tian Y, Tu MJ, Ho PY, and Jilek JL (2016) MicroRNA pharmacopigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. *Drug Metab Dispos* **44**:308–319.
- Zanger UM, Turpeinen M, Klein K, and Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. *Anal Bioanal Chem* **392**:1093–1108.
- Zhou SF (2009a) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. *Clin Pharmacokinet* **48**:689–723.
- Zhou SF (2009b) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. *Clin Pharmacokinet* **48**:761–804.
- Zoller MJ and Smith M (1982) Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. *Nucleic Acids Res* **10**:6487–6500.

**Address correspondence to:** Ai-Ming Yu, Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, 2700 Stockton Blvd, Ste 2130, Oak Park Research Building, Sacramento, CA 95817. E-mail: aimyu@ucdavis.edu